Delving into the Latest Updates on Sibutramine maleate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

DAT x NET x SERT

Action

inhibitors

Mechanism

Dopamine reuptake inhibitors, NET inhibitors(Norepinephrine transporter inhibitors), Serotonin reuptake inhibitors

Therapeutic Areas

Other Diseases

Active Indication

Anorexia Nervosa

Inactive Indication-

Originator Organization

Abbott Laboratories

Active Organization

Abbott Laboratories

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

South Korea (01 Dec 2011),

Anorexia Nervosa

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC17H26ClN

InChIKeyUNAANXDKBXWMLN-UHFFFAOYSA-N

CAS Registry106650-56-0

View All Structures (2)

Obesity is a major public health concern, and the search for useful pharmacologic interventions is ongoing. This study aims to develop a comprehensive series of assessments to directly assess eating behavior, cognitive functioning, and psychological functioning under sibutramine and placebo conditions.

Start Date01 Feb 2009

Sponsor / Collaborator

The New York State Psychiatric Institute

[+1]

100 Clinical Results associated with Sibutramine maleate

Login to view more data

100 Translational Medicine associated with Sibutramine maleate

Login to view more data

100 Patents (Medical) associated with Sibutramine maleate

Login to view more data

1,793

Literatures (Medical) associated with Sibutramine maleate

01 Jun 2025·Food Chemistry

High-throughput screening of new psychoactive substances and related compounds in food by UHPLC-Q/Orbitrap

Article

Author: Wu, Wenlin ; Huang, Xia ; Liu, Shiyao ; Chen, Xiaoqi ; Zhou, Yan ; Wan, Yuping ; Xia, Bing ; Guo, Tianrong ; Shi, Peiyu ; Xiao, Quanwei ; Zhang, Min

Currently, there is concern about food products to which new psychoactive substances (NPS) have been added illegally. However, rapid, high-sensitivity, and high-throughput screening methods for such harmful substances have not been reported yet. In this study, a high-throughput non-targeted screening strategy was developed based on UHPLC-Q/Orbitrap. First, optimized pretreatment methods for typical high-risk matrices were established. Second, an accurate, efficient, and scalable high resolution mass spectrometry database containing 206 NPS and related compounds was constructed. The fragmentation pathways of three different types of fentanyl-related compounds were then systematically investigated to enhance compound identification. Additionally, a non-targeted screening strategy was developed using warning ions derived from 24 fentanyl-related compounds, streamlining the identification of NPS. This strategy was applied to 100 food samples with possible illegal additives and demonstrated its effectiveness. In summary, this study provides robust technical support for regulatory authorities in combating the illegal addition of food products.

01 May 2025·Nutrition Reviews

The Effectiveness of Nonsurgical Interventions for Weight Loss Maintenance in Adults: An Updated, GRADE-Assessed Systematic Review and Meta-Analysis of Randomized Clinical Trials

Review

Author: Shidfar, Farzad ; Nazarian, Amirhossein ; Hemmati, Amirhossein ; Hasan Rashedi, Minoo ; Shoaibinobarian, Nargeskhatoon ; Zeraattalab-Motlagh, Sheida ; Ghoreishy, Seyed Mojtaba ; Fernandez, Maria Luz ; Noormohammadi, Morvarid ; Movahed, Samira

AbstractContextToday, there are many discussions about the best way to maintain weight and prevent weight regain after a period of weight loss.ObjectivesThe aim of this study was to summarize, based on data from randomized clinical trials (RCTs), the impact of nonsurgical interventions for adults’ weight loss maintenance.Data SourcesThe Medline (PubMed), Scopus, and Web of Science databases were reviewed during June 2023.Data ExtractionMeta-analyses assessing the impacts of nonsurgical interventions for weight loss maintenance were conducted. Effect sizes of nutritional interventions were recalculated by applying a random-effects model. The Grading of Recommendations, Assessment, Development, and Evaluation framework was implemented to determine evidence certainty.ResultsMeta-analysis of data from a total of 56 RCTs (n = 13 270 participants) represented a significant weight reduction after behavior and lifestyle interventions (mean difference [MD], –0.64 kg [95% CI, –1.18 to –0.09]; I2 = 89.5%; P < .001 for heterogeneity). Pharmacological interventions had also a significant effect on weight change during the weight maintenance phase (MD, –2.57 kg [95% CI, –3.12 to –2.02]; I2 = 91.6%; P < .001 for heterogeneity). The weight loss reduction from pharmacological interventions was greater with sibutramine (MD, –2.57; 95% CI: –3.12 to –2.02). Additionally, diet intervention and dietary and physical activity strategies were associated with a negligible trending decrease in weigh regain (respectively: MD, –0.91 kg [95% CI, –2.18 to 0.36], I2 = 55.7%, P = .016 for heterogeneity; and MD, –0.3 kg [95% CI, –4.13 to 3.52], I2 = 94.1%, P < .001).ConclusionThe findings of this review indicate there is a favorable impact of behavior-based interventions and antiobesity medications on weight maintenance.Systematic Review RegistrationPROSPERO registration no CRD42023468056.

04 Mar 2025·Clinical Toxicology

Presence of sibutramine and sildenafil in weight loss dietary supplements: a case series with analytical and clinical investigation

Article

Author: Pietri, Tessa ; Carles, Marie ; Fabresse, Nicolas ; Richez, Magali ; Micallef, Joelle ; Corteggiani-Giraud, Clara ; Lacarelle, Bruno ; Solas-Chesneau, Caroline

INTRODUCTIONThe use of weight loss supplements is increasing, often driven by online marketing. However, many of these supplements are adulterated with undeclared pharmaceutical substances, potentially posing significant health risks. We investigated the presence of sibutramine and sildenafil in weight loss supplements and assessed the associated clinical outcomes.MATERIALS AND METHODSA total of 12 weight loss supplement samples (capsules, tea, and coffee bags) were analyzed using liquid chromatography-high resolution mass spectrometry. Demographic and clinical data were collected by the Marseille Regional Pharmacovigilance Centre from 29 patients who reported using these products.RESULTSAll samples were found to contain sibutramine, with concentrations ranging from 7.5 mg to 15.4 mg per unit. Sildenafil was detected in all samples, with concentrations ranging from 1.7 mg to 4.8 mg per unit. Clinical data from 29 users showed significant weight loss, with an average of 7.5 kg after 37 days of use. Adverse effects included anorexia (n = 15), tachycardia (n = 13), insomnia (n = 2) and chest pain (n = 4). In some cases, more serious effects such as seizures and dependence were observed.DISCUSSIONBoth sibutramine and sildenafil were withdrawn from the market due to cardiovascular risks. As such, the unregulated use of these products pose a serious risk to public health, particularly in individuals with underlying cardiovascular disease.CONCLUSIONWe detected sibutramine and sildenafil in all 12 weight loss supplements tested, which highlights the need for stricter regulation and monitoring.

100 Deals associated with Sibutramine maleate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	A08AA10	-

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Anorexia Nervosa	South Korea	Abbott Laboratories	01 Dec 2011

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01170364 (CTgov)	Phase 4	Obesity	14	Placebo+Sibutramine (Sibutramine)	lhvjwrhrml(pnubtjfacc) = tbuwiuzmic mirfqjlwae (iruvgwqleq, kbjiwfglir - otwbqnfiva) View more	-	31 Jul 2017
				Placebo+Sibutramine (Placebo)	lhvjwrhrml(pnubtjfacc) = qtygrrcplo mirfqjlwae (iruvgwqleq, cxhukgntbc - rrlstwrhno) View more
NCT00537810 (CTgov)	Phase 4	Binge-Eating Disorder \| Obesity	104	Sibutramine (Sibutramine)	immdomypdx(vjchfzjuyq) = pbyayrgldf vkxiwpsbbg (amspwzlyez, nbthmpufix - qphehikgre) View more	-	12 Dec 2014
				Placebo (Placebo)	immdomypdx(vjchfzjuyq) = xafpmzreje vkxiwpsbbg (amspwzlyez, wtvsuwnefl - cbspzvxwaw) View more
NCT00993421 (CTgov)	Phase 2	Obesity	343	Placebo LY377604 (Placebo)	relhqsbxtt(isljcqswth) = vgqupptfha leqrwwsuat (jrwafnzzon, dgwjaaemxt - watoplnqso) View more	-	02 Jun 2011
				Placebo Metoprolol+LY377604 (LY377604 (75 mg))	relhqsbxtt(isljcqswth) = ijjmfspnex leqrwwsuat (jrwafnzzon, sjyxatxpsj - rtqdxsxqxj) View more